Stereochemistry | ABSOLUTE |
Molecular Formula | C35H45FN5O9S.Na |
Molecular Weight | 753.813 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[H][C@@]12C[C@H](CN1C(=O)[C@H](CCCCCC=C[C@@H]3C[C@]3(NC2=O)C(=O)[N-]S(=O)(=O)C4CC4)NC(=O)OC(C)(C)C)OC(=O)N5CC6=C(C5)C(F)=CC=C6
InChI
InChIKey=GXYYUDQAGCVAGJ-HHGSPMIASA-M
InChI=1S/C35H46FN5O9S.Na/c1-34(2,3)50-32(45)37-27-13-8-6-4-5-7-11-22-17-35(22,31(44)39-51(47,48)24-14-15-24)38-29(42)28-16-23(19-41(28)30(27)43)49-33(46)40-18-21-10-9-12-26(36)25(21)20-40;/h7,9-12,22-24,27-28H,4-6,8,13-20H2,1-3H3,(H3,37,38,39,42,44,45);/q;+1/p-1/b11-7-;/t22-,23-,27+,28+,35-;/m1./s1
Danoprevir (ITMN-191, RG7227) is a peptidomimetic inhibitor of the NS3/4A protease of HCV. The second-generation, direct acting antiviral agent was originated by Array BioPharma and InterMune (a subsidiary of Roche), and then sold to Roche. Danoprevir has demonstrated potency against mutant HCV strains. Phase III development is underway for HCV infections in China, and phase II development for the same indication is underway in the US, Australia, Brazil, Canada, Mexico, New Zealand, Puerto Rico, Taiwan and certain European countries.
Originator
Approval Year
PubMed
Sample Use Guides
In a Phase I study, danoprevir monotherapy was administered for 14 days in ascending doses ranging from 200 to 600 mg per day: The antiviral effectiveness increased in a dose-dependent manner, with a 14-day time-averaged effectiveness of 0.95 at the lowest dose (100 mg twice daily) and 0.99 at the highest dose (200 mg three times daily).
Route of Administration:
Other